ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO0134

Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected with SARS-CoV-2

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Speer, Claudius, University of Heidelberg, Heidelberg, Germany
  • Nusshag, Christian, University of Heidelberg, Heidelberg, Germany
  • Kälble, Florian, University of Heidelberg, Heidelberg, Germany
  • Klein, Katrin, University of Heidelberg, Heidelberg, Germany
  • Süsal, Caner, University of Heidelberg, Heidelberg, Germany
  • Schnitzler, Paul, University of Heidelberg, Heidelberg, Germany
  • Zeier, Martin G., University of Heidelberg, Heidelberg, Germany
  • Morath, Christian, University of Heidelberg, Heidelberg, Germany
  • Benning, Louise, University of Heidelberg, Heidelberg, Germany
Background

Seroconversion rates following infection and vaccination are lower in dialysis patients compared to healthy controls. There is an urgent need for the characterization of humoral responses and success of a single-dose SARS-CoV-2 vaccination in previously infected dialysis patients.

Methods

We performed a dual-center study with 43 dialysis patients after BNT162b2 vaccination and 25 dialysis patients after PCR-confirmed COVID-19. Single-dose vaccination was performed in 13 previously infected patients. Anti-S1 IgG, neutralizing antibodies, and antibodies against various SARS-CoV-2 epitopes were measured 6 weeks after the first vaccination or onset of COVID-19 and 3 weeks after single-dose vaccination.

Results

Previously infected patients without vaccination showed a significantly higher neutralizing capacity than patients vaccinated twice (median (IQR) percent inhibition 88.0 (71.5–95.5) vs. 50.7 (26.4–81.0); P=0.018). After one single vaccine dose, infected individuals generated 15- to 34-fold higher levels of anti-S1 IgG than age- and dialysis vintage-matched patients after infection or two-time vaccination with a median (IQR) index of 274 (151–791) compared to 18 (8–41) and 8 (1–21) (for both P<0.001). With a median (IQR) percent inhibition of 97.6 (97.2-98.9), the neutralizing capacity of SARS-CoV-2 antibodies was significantly higher in previously infected patients compared to other groups (for both P<0.01). Bead-based analysis showed high antibody reactivity against various SARS-CoV-2 spike protein epitopes after single-dose vaccination in previously infected patients.

Conclusion

Single-dose vaccination in previously infected dialysis patients induced a strong and broad antibody reactivity against various SARS-CoV-2 spike protein epitopes with high neutralizing capacity.